Tisotumab vedotin
| File:Vedotin ADCs.svg | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Tissue factor (TF) |
| Clinical data | |
| Trade names | Tivdak |
| Other names | Tisotumab vedotin-tftv |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 68–82% (MMAE) |
| Metabolism | Liver, by CYP3A4 (MMAE) |
| Metabolites | MMAE |
| Elimination half-life | 4 days |
| Excretion | Fecal, renal (MMAE) |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer.[1] It is a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. It is administered by infusion into a vein.[1]
Tisotumab vedotin was approved for medical use in the United States in September 2021,[1][4] and in the European Union in March 2025.[2][3] The US Food and Drug Administration considers it to be a first-in-class medication.[5]
Adverse effects
[edit | edit source]In the United States, Tivdak carries a boxed warning for ocular toxicity, which occurs in up to 60% of treated patients.[1] In clinical trials, the most common forms of ocular toxicity were dry eye, conjunctivitis, corneal damage, and blepharitis.[1]
Other common adverse effects include bleeding (occurring in approximately 60% of patients, most often nosebleed) and peripheral neuropathy (42% of patients).[1] Like all drugs containing MMAE, tisotumab vedotin can cause inflammation of the lungs.[1]
Mechanism of action
[edit | edit source]The antibody portion of tisotumab vedotin (tisotumab) binds to and forms a complex with tissue factor, a molecule expressed on the surface of cancer cells. This complex is then taken up into the cell, where tisotumab vedotin is broken down by proteolytic cleavage, releasing MMAE, which stops the cell cycle and kills the cell by apoptosis.[1]
History
[edit | edit source]Tisotumab vedotin was developed by Genmab in Utrecht, the Netherlands, and Copenhagen, Denmark, with the code name TF-011-MMAE.[6] In September 2021, tisotumab vedotin was granted accelerated approval by United States Food and Drug Administration for the use of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.[7]
Society and culture
[edit | edit source]Legal status
[edit | edit source]In April 2024, tisotumab vedotin was granted traditional approval by the US Food and Drug Administration (FDA) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.[8] Tisotumab vedotin previously received accelerated approval for this indication.[8]
In January 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tivdak, intended for the treatment of recurrent or metastatic cervical cancer.[2] The applicant for this medicinal product is Pfizer Europe MA EEIG.[2] Tisotumab vedotin was authorized for medical use in the European Union in March 2025.[2][3]
Names
[edit | edit source]Tisotumab vedotin is the international nonproprietary name.[9] Tivdak is the brand name for tisotumab vedotin in the United States.[4]
References
[edit | edit source]- ^ a b c d e f g h i j Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b c d e Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value). Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value). Error creating thumbnail: This article incorporates text from this source, which is in the public domain.
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value). Error creating thumbnail: This article incorporates text from this source, which is in the public domain.
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
External links
[edit | edit source]- Clinical trial number NCT03438396 for "A Trial of Tisotumab Vedotin in Cervical Cancer" at ClinicalTrials.gov
- Clinical trial number NCT03245736 for "Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors" at ClinicalTrials.gov
- Clinical trial number NCT02001623 for "Tisotumab Vedotin (HuMax-TF-ADC) Safety Study in Patients With Solid Tumors" at ClinicalTrials.gov
- Clinical trial number NCT02552121 for "Tisotumab Vedotin (HuMax-TF-ADC) Safety Study in Patients With Solid Tumors" at ClinicalTrials.gov
Lua error in mw.title.lua at line 392: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal'). Lua error in Module:Authority_control at line 153: attempt to index field 'wikibase' (a nil value).